Rigel Pharmaceuticals Inc... (RIGL)
NASDAQ: RIGL
· Real-Time Price · USD
19.51
0.75 (4.00%)
At close: Jun 27, 2025, 3:59 PM
19.10
-2.10%
After-hours: Jun 27, 2025, 05:08 PM EDT
Rigel Pharmaceuticals Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|
| Contract revenues from collaborations Revenue | 34.38M | -42.76M | 39.02M | 75.73M | 40.36M | 8.7M | 30.56M |
| Contract revenues from collaborations Revenue Growth | -180.39% | -209.58% | -48.47% | +87.64% | +364.10% | -71.55% | n/a |
| Discounts and allowances Revenue | -65.02M | 147.06M | -31.8M | -18.18M | n/a | n/a | n/a |
| Discounts and allowances Revenue Growth | -144.22% | -562.37% | +74.98% | n/a | n/a | n/a | n/a |
| Gross product sales Revenue | 209.92M | 104.29M | 108.52M | 81.19M | n/a | n/a | n/a |
| Gross product sales Revenue Growth | +101.28% | -3.90% | +33.67% | n/a | n/a | n/a | n/a |
| License Revenue | 14M | n/a | 76.72M | 63.01M | n/a | n/a | n/a |
| License Revenue Growth | n/a | n/a | +21.76% | n/a | n/a | n/a | n/a |
| Product sales, net Revenue | 144.9M | n/a | n/a | n/a | n/a | n/a | n/a |
| Product sales, net Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 27.71M | 29.52M | 27.04M | 28.05M | 28.45M | 26.85M | 24.86M | 26.31M | 27.73M | 32.17M | 25.9M | 26.98M | 27.4M | 24.52M | 22.88M | 22.38M | 22.12M | 21.82M | 17.43M | 18.92M | 18.43M | 18.31M | 18.12M | 18.21M | 19.95M | 21.37M | 18.07M | 17.07M | 13.49M | 14.65M | 7.95M | 7.82M | 7.41M | 7.15M | 4.56M | 4.77M | 4.42M | 4.72M | 4.28M | 4.1M | 4.72M |
| Selling, General, and Administrative Revenue Growth | -6.11% | +9.16% | -3.58% | -1.41% | +5.96% | +8.02% | -5.51% | -5.13% | -13.81% | +24.23% | -4.02% | -1.53% | +11.77% | +7.16% | +2.23% | +1.16% | +1.39% | +25.17% | -7.88% | +2.66% | +0.64% | +1.05% | -0.48% | -8.71% | -6.66% | +18.27% | +5.85% | +26.53% | -7.93% | +84.40% | +1.62% | +5.53% | +3.59% | +56.93% | -4.52% | +7.94% | -6.31% | +10.41% | +4.32% | -13.10% | n/a |
| Research and Development Revenue | 8.44M | 5.63M | 6.18M | 5.54M | 6.03M | 3.19M | 6.47M | 4.77M | 10.09M | 15.37M | 14.67M | 14.77M | 15.47M | 13.3M | 18.3M | 16.81M | 16.83M | 15.14M | 14.6M | 14.21M | 16.15M | 14.25M | 14.46M | 13.23M | 10.95M | 13.77M | 11.1M | 10.8M | 11.24M | 11.56M | 10.81M | 11.52M | 12.38M | 11.63M | 16.17M | 17.47M | 18.17M | 16.56M | 15.5M | 15.06M | 15.7M |
| Research and Development Revenue Growth | +49.79% | -8.90% | +11.59% | -8.07% | +89.14% | -50.80% | +35.69% | -52.70% | -34.34% | +4.77% | -0.68% | -4.57% | +16.31% | -27.30% | +8.88% | -0.11% | +11.15% | +3.68% | +2.72% | -11.98% | +13.35% | -1.49% | +9.35% | +20.80% | -20.47% | +24.06% | +2.78% | -3.96% | -2.76% | +6.97% | -6.21% | -6.88% | +6.38% | -28.06% | -7.43% | -3.88% | +9.72% | +6.85% | +2.94% | -4.10% | n/a |